ALSO NOTED: Medicure raises $40M; FDA wants more data on Creon; Genta launches Phase III; and much more...

> Medicure has struck two deals to raise $40 million. Release

> The FDA has issued an approvable letter for Solvay's Creon--a pancreatic enzyme for the treatment of pancreatic exocrine insufficiency--but wants more data before it can give the therapy its full blessing. Release

> Genta announced that the first patients have been enrolled in the company's confirmatory Phase III trial of Genasense Injection in advanced melanoma. Release

> Sirtris Pharmaceuticals has initiated a Phase IIa clinical trial to evaluate its SRT501 product candidate in patients with Type 2 Diabetes whose glucose levels are not adequately controlled by their metformin treatment. Release 

> Perrigo has launched a patent dispute with Adams Respiratory. Release

> A new research report concludes that Gilead may be stealing GlaxoSmithKline's "Best anti-HIV drug maker" crown, thanks to Gilead's drug-combo pill Atripla. Release

> Merck may have had a near-death experience, but now it's found a survival strategy: fight every Vioxx case as if it were the only one. FiercePharma

> Pharma observers just won't stop matchmaking. A Credit Suisse analyst wants Pfizer to buy out Wyeth, noting that Wyeth stock has plummeted 19 percent since July 23 on a string of bad news. But Wyeth's pipeline is promising, and its biotech drugs are strong--so it's a bargain. FiercePharma 

And Finally... The race is on to produce synthetic life. FierceBioResearcher

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.